MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.880
-0.030
-0.77%
After Hours: 3.930 +0.05 +1.29% 16:47 05/20 EDT
OPEN
3.940
PREV CLOSE
3.910
HIGH
4.070
LOW
3.700
VOLUME
1.68M
TURNOVER
0
52 WEEK HIGH
19.37
52 WEEK LOW
3.520
MARKET CAP
722.74M
P/E (TTM)
-1.4557
1D
5D
1M
3M
1Y
5Y
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 5d ago
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Zacks · 05/06 14:07
Nektar Therapeutics Q1 EPS $(0.49) Up From $(0.68) YoY, Sales $24.80M Up From $23.65M YoY
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.49) per share. This is a 27.94 percent increase over losses of $(0.68) per share from the same period last year. The company reported $24.80 million in
Benzinga · 05/05 22:15
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:55
Nektar Therapeutics GAAP EPS of -$0.49 beats by $0.21, revenue of $24.8M misses by $0.09M
Nektar Therapeutics press release (NASDAQ:NKTR): Q1 GAAP EPS of -$0.49 beats by $0.21. Revenue of $24.8M (+4.9% Y/Y) misses by $0.09M. Cash and investments in marketable securities at March 31, 2022
Seekingalpha · 05/05 20:49
BRIEF-Nektar Therapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/05 20:45
-- Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $24.8M
MT Newswires · 05/05 16:59
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:15
More
No Data
Learn about the latest financial forecast of NKTR. Analyze the recent business situations of Nektar Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

7.69%Strong Buy
0.00%Buy
76.92%Hold
15.38%Under-perform
0.00%Sell
Analyst Price Target
The average NKTR stock price target is 5.83 with a high estimate of 12.00 and a low estimate of 3.000.
High12.00
Average5.83
Low3.000
Current 3.880
EPS
Actual
Estimate
-0.70-0.53-0.35-0.18
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 420
Institutional Holdings: 243.15M
% Owned: 130.53%
Shares Outstanding: 186.27M
TypeInstitutionsShares
Increased
85
12.00M
New
41
3.42M
Decreased
63
10.75M
Sold Out
37
2.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.90%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Robert Chess
Chief Executive Officer/President/Director
Howard Robin
Chief Financial Officer/Chief Operating Officer/Senior Vice President
Gilbert Labrucherie
Senior Vice President - Finance/Chief Accounting Officer
Jillian Thomsen
Senior Vice President/General Counsel
Mark Wilson
Senior Vice President
Brian Kotzin
Senior Vice President
John Northcott
Senior Vice President
Dimitry Nuyten
Other
Jonathan Zalevsky
Lead Director/Independent Director
Roy Whitfield
Independent Director
Jeff Ajer
Independent Director
Diana Brainard
Independent Director
Myriam Curet
Independent Director
Karin Eastham
Independent Director
R. Scott Greer
No Data
No Data
About NKTR
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.